The Pink Ribbon Turns 25: The Estée Lauder Companies’ Breast Cancer Campaign Reaches 25 Year Milestone
The Estée Lauder Companies honors the 25th Anniversary of The Breast Cancer Campaign (formerly known as The Breast Cancer Awareness Campaign) and the co-creation of the iconic pink ribbon by its visionary founder, the late Evelyn H. Lauder.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170928005489/en/
The 2017 Estée Lauder Companies' Breast Cancer Campaign ad visual (Graphic: Business Wire)
25 years ago there was no pink ribbon. Women around the world were dying from breast cancer and there was very little discussion about it. Mrs. Lauder saw an urgent need to bring breast cancer to the forefront and put a spotlight on this world health issue. In 1992, she became a pioneer for the breast cancer movement, co-creating the pink ribbon and launching The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign). A year later, she founded the Breast Cancer Research Foundation® (BCRF), a non-profit organization, to generate funding solely dedicated to breast cancer research. Today, the pink ribbon is the ubiquitous symbol of breast health and The Campaign is a global leading voice for breast cancer, igniting a worldwide movement that has funded innovative research and awareness, and inspired meaningful action.
To mark the 25th Anniversary, The Estée Lauder Companies has a new mission: to create a breast cancer-free world. A bold, thought-provoking visual of a tattered pink ribbon is being introduced, showing the wear and tear of 25 years of hard work, dedication and impact trying to cure this disease. It also represents the hope that in 25 years, there will be no need for a pink ribbon; breast cancer will be committed to the history books. The Campaign no longer carries the word “Awareness” as breast cancer now has the global spotlight it deserves, moving into the future with a new rally – it’s time to end breast cancer.
The Campaign is now active in more than 70 countries around the world, partnering with more than 60 regional organizations to address areas of most critical need. The Campaign has raised more than $70 million to support global research, education and medical services, funding 225 medical research grants through BCRF ($56 million from total funds raised). To date:
- Breast cancer mortality rates have decreased by 38% since the late 1980s.1
- Five-year survival rates are better than 90% when breast cancer is found early2
- Treatments are being customized to a person’s type of breast cancer, as breast cancer was revealed to be not one disease, but several different types
- Surgery is not as invasive, and most women can have a lumpectomy and not a full breast removal (mastectomy)
William P. Lauder, Executive Chairman of The Estée Lauder Companies Inc., continues to honor the legacy of his late mother and proudly champions The Campaign’s work worldwide stating, “Supporting the development of critical research, driving awareness, and helping to eliminate the cultural barriers that can prevent the identification and treatment of breast cancer has been our core Company focus since my mother Evelyn H. Lauder founded The Breast Cancer Campaign 25 years ago. I am continuously humbled and energized by the passion and care exhibited by our employees and the tireless dedication of our partners—whose work is getting us closer to a global cure each and every day. As a Company, our commitment has not and will not waver.”
The Campaign unites partners and influencers worldwide, demonstrating the power of taking action together and inspiring others to make a difference. “Throughout my travels as Global Ambassador for The Estée Lauder Companies’ Breast Cancer Campaign, I’ve seen the hope that advancing breast cancer research is bringing,” said Elizabeth Hurley, Global Ambassador for The Breast Cancer Campaign. “I’ve seen first-hand the strength of those fighting breast cancer and the strength of friends and family who are supporting them in their fight, and I truly believe that together we can help turn the corner and bring breast cancer to an end.”
The Estée Lauder Companies is launching global efforts to support The Campaign:
- Largest-ever one-year commitment of $8 million in financial contributions
- A social fundraising effort, in which The Estée Lauder Companies will donate $25 to fund a half-hour of breast cancer research through BCRF for every unique post on Instagram or Twitter with both #PinkRibbon25 and #ELCdonates between September 15, 2017 and October 31, 2017, with the goal of funding a maximum of 500 research hours
- Illumination of buildings, monuments and landmarks worldwide in glowing pink lights to raise awareness of breast health – including the Empire State Building, New York City and the Eiffel Tower, Paris
- Release of a documentary short film, “Unraveling the Pink Ribbon: Creating a Breast Cancer-Free World,” directed by Sophy Holland, honoring Mrs. Lauder and highlighting progress made
- Distribution of informational brochures and pink ribbons at The Estée Lauder Companies’ beauty brand counters worldwide
“The Estée Lauder Companies has long been committed to making an impact on communities around the world, and our efforts through The Breast Cancer Campaign are a reflection of that purpose,” said Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies Inc. “The awareness we’ve brought to the movement brings us great pride, and fuels the next – and what we hope to be the last - stage of The Campaign: ending breast cancer.”
The following brands of The Estée Lauder Companies will support The Campaign's mission: Aveda, Bobbi Brown, Bumble and bumble, Clinique, Darphin, DKNY, Donna Karan, Estée Lauder, Jo Malone London, La Mer, Lab Series, Origins, Prescriptives, Smashbox, Tom Ford Beauty and Tory Burch. Each will contribute by selling Pink Ribbon Products or making donations to BCRF and/or other charitable organizations around the world. This assortment differs by country and organization.
To support the 25th Anniversary of The Estée Lauder Companies’ Breast Cancer Campaign, visit bcacampaign.com, follow on social media @bcacampaign and use #PinkRibbon25.
ABOUT THE ESTÉE LAUDER COMPANIES INC.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA and Too Faced.
1. Source: American Cancer Society Cancer Facts and Figures 2017 (https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html)
2. Source: American Cancer Society Understanding Breast Cancer Survival Rates (https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html)
The Estée Lauder Companies
Bari Seiden-Young, 212-572-4475
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
GSMA: Multiple Mobile Operators Launch Live Commercial Low Power Wide Area Networks in Licensed Spectrum Worldwide21.2.2018 12:00 | Tiedote
The GSMA today announced that momentum behind Mobile IoT, or licensed Low Power Wide Area (LPWA), networks continues to grow on a global basis. To date, 23 mobile operators have commercially launched 41 Mobile IoT networks worldwide across both NB-IoT1 and LTE-M2. This growth is supported by 34 IoT Labs and an expanding community of over 800 organisations in the GSMA’s Mobile IoT Innovators Community. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections. “2018 is the year that Mobile IoT networks will scale. We have seen huge growth in the availability of commercial networks in licensed spectrum and anticipate seeing many more launches this year. This is underpinned by an expanding community of organisations developing innovative new solutions and a number of IoT Labs helping companies to test out new products and services,” said Alex Sinclair, Chief Technology Officer, GSMA. “Mobile IoT ne
Clientron to Present Its POS Innovation at EuroCIS 201821.2.2018 12:00 | Tiedote
Clientron Corp., a global leading provider of POS, thin client, and embedded systems, will display its latest POS solutions for the retail market at the world’s leading retail show, EuroCIS 2018, from February 27 to March 1, 2018 in Dusseldorf, Germany. At its Booth (Hall 10, Booth E73), Clientron will introduce its innovative POS terminals and various built-in POS peripherals available on the market today in order to meet the demands of omnicommerce experience. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005007/en/ Clientron to present its POS innovation at EuroCIS 2018 At the event, Clientron's displays will include: the innovative PST650 all-in-one POS terminal with a built-in high speed thermal printer and a small, lightweight form factor for counter space savings; the most affordable POS terminal, PT2000, in a fanless design with long life span support to both entry and mainstream POS market segments; and the ne
Fake Medicines Continue to Threaten Consumers – EU Member States have an Obligation to Act21.2.2018 11:12 | Tiedote
According to The Alliance for Safe Online Pharmacy in the EU (ASOP EU), the illegal manufacturing and distribution of fake medicines is an enormous and growing public health risk with an untold cost to lives. "Vast profits are made by organized criminal gangs who often use the proceeds to support other criminal activities. The Internet provides the ideal channel to buy illegally distributed fake medicines. Price, convenience and secrecy have driven consumer demand, creating the perfect environment for over 35,000 illegally operating websites." Under article 85d of the Falsified Medicines Directive, each EU Member State is obliged to raise awareness about the risks of buying medicines online. To better understand how countries are meeting these obligations to educate and protect consumers, the European Union’s Alliance for Safe Online Pharmacy (ASOP EU) and the European Alliance for Access to Safe Medicines (EAASM), has convened a series of discussions with many Member States. Based on
Triton Digital Integrates Platform 161 with a2x® to Provide Marketers and Buyers with Access to Premium Digital Audio Advertising Inventory21.2.2018 11:00 | Tiedote
Triton Digital®, the global technology and services leader to the digital audio and podcast industry, announced today the integration of its audio advertising marketplace, a2x®, with Platform 161, a leading DSP for advertisers, agencies and publishers. The integration provides Platform 161’s advertisers with the ability to add online audio from top-tier broadcasters and streaming music services to their programmatic, omnichannel buys through both open auction and private marketplace (PMP) deals. “We are proud to partner with Triton Digital to provide our marketers with access to a wide range of digital audio inventory from music services, live streaming radio, podcasts, and more through the a2x programmatic audio marketplace,” said Marco Kloots, CEO at Platform 161. “The personal, highly-engaging nature of digital audio will undeniably enhance our marketers omnichannel buys, enabling them to both scale their buys and connect with their target audience in a native, immersive manner acro
Posiflex Showcases Stylish New Line of Touch Screen Terminals and Self-Service & Interactive Kiosks at EuroCIS 201821.2.2018 11:00 | Tiedote
Posiflex Technology, Inc. unveils an entirely new line of dynamic touch screen terminals that embodies a new era for Posiflex and point-of-sale hardware – the RT Series. With an elegant housing and a strikingly thin profile, the RT Series brings a modern aesthetic to the counter and makes a retail business look even more attractive. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005002/en/ Make Your Business Look More Attractive with Posiflex RT Series (Photo: Business Wire) Available in 15” (4:3) screen or 15.6” (16:9) widescreen, the RT Series provides multiple CPU selection from Intel Celeron all the way to Core i5 CPU to fit each unique need. The patented fanless technology allows the unit to run silently and perform in harsh environments that involves dust and liquid spills. “POS terminal is no longer just a cold and hard business tool; it has evolved to be an extension of the brand offering a more dynamic in-store
Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies21.2.2018 10:00 | Tiedote
Regulatory News: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, and Ipsen (Euronext: IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies. Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance to invest in opportunities in Arix’s new and existing businesses. In return, Ipsen will contribute research, development and commercial expertise to the partnership. Arix and Ipsen will collaborate to identify opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients. Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: “This agreement brings together Ipsen’s deep expertise in drug development and commercialization with Ar
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme